Showing results (51-60 of 93) with videos related to
Sort By:
Pageof 10
Bone Marrow Transplantation|January 4, 2026
Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWPPatricia López-Pereira, Ali Bazarbachi, Ambroise Marçais, et al.Blood Advances|January 30, 2023
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysisCatherine Thieblemont, Bettina Altmann, Fabian Frontzek, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphomaChristian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.Lancet (London, England)|June 19, 2022
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trialManali Kamdar, Scott R Solomon, Jon Arnason, et al.Bone Marrow Transplantation|April 15, 2025
Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma GroupCarmen Martínez, Irma Khvedelidze, Mathilde Fekom, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2025
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM StudyManali Kamdar, Scott R Solomon, Jon Arnason, et al.Bone Marrow Transplantation|June 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, et al.Frontiers in Immunology|October 13, 2023
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working partyOlaf Penack, Christophe Peczynski, Christian Koenecke, et al.Blood|November 5, 2016
Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantationDaniel Fuerst, Christine Neuchel, Dietger Niederwieser, et al.Hematology (Amsterdam, Netherlands)|February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trialHans Salwender, Niels Weinhold, Axel Benner, et al.Pageof 10